Institute for Pharmacy and Food Chemistry, Justus Maximilians University Würzburg, Am Hubland, 97074, Würzburg, Germany.
Institute for Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
ChemMedChem. 2021 Jan 19;16(2):340-354. doi: 10.1002/cmdc.202000548. Epub 2020 Oct 16.
Inhibition of coronavirus (CoV)-encoded papain-like cysteine proteases (PL ) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure-activity relationships (SAR) of the noncovalent active-site directed inhibitor (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS-CoV PL . Moreover, we report the discovery of isoindolines as a new class of potent PL inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS-CoV-2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS-CoV PL are valuable starting points for the development of new pan-coronaviral inhibitors.
抑制冠状病毒(CoV)编码的木瓜样半胱氨酸蛋白酶(PL )是治疗这些重要人类病原体感染的一种有吸引力的策略。在此,我们报告非共价活性位点定向抑制剂(R)-5-氨基-2-甲基-N-(1-(萘-1-基)乙基)苯甲酰胺(2b)的构效关系(SAR),该抑制剂已知与 SARS-CoV PL 的 S3 和 S4 口袋结合。此外,我们还报道了异吲哚啉作为一类新型强效 PL 抑制剂的发现。这些研究还提供了对该抑制剂类结合模式的更深入了解。重要的是,抑制剂也被证实可以抑制细胞培养中的 SARS-CoV-2 复制,这表明由于靶蛋白酶的高度结构相似性,针对 SARS-CoV PL 鉴定的抑制剂是开发新型泛冠状病毒抑制剂的有价值的起点。